-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RS-1805 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RS-1805 in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RS-1805 in Ulcerative Colitis Drug Details: RS-1805 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RS-0139 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RS-0139 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RS-0139 in Non-Small Cell Lung Cancer Drug Details: RS-0139 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enitociclib in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enitociclib in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enitociclib in Non-Hodgkin Lymphoma Drug Details: Enitociclib is under development for...
-
Product Insights
RS & W Drift Mine
The RS & W Drift Mine is a coal mine in United States. It is currently in operation. Empower your strategies with our RS & W Drift Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and...
-
Product Insights
RS Cogeneration Plant
RS Cogeneration Plant is a thermal project located in Louisiana, United States. The project is owned by RS Cogen, LLC.. The project came online in 2002. Empower your strategies with our RS Cogeneration Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or...
-
Product Insights
NewNet Present Value Model: Akeso Inc’s Ivonescimab
Empower your strategies with our Net Present Value Model: Akeso Inc's Ivonescimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Monalizumab
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Monalizumab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Baxdrostat
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Baxdrostat report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Novartis AG’s Opnurasib
Empower your strategies with our Net Present Value Model: Novartis AG's Opnurasib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Tozorakimab
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Tozorakimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.